83435-61-4

Upstream product

• 84793-24-8 N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine N-carboxyanhydride 
• 83402-63-5 tert-butyl N-(2,3-dihydro-1H-inden-2-yl)glycinate 
• 80828-26-8 N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine hydrochloride 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 2975-41-9 2,3-dihydro-1H-inden-2-amine 
• 615-13-4 2-indanone 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 
• 2524-64-3 chlorophosphoric acid diphenyl ester 
• 2338-18-3 2-aminoindane hydrochloride 
• 80828-38-2 N-<(S)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 71666-98-3 tert-butyl glycinate hydrophosphite 
• 64920-29-2 2-oxo-4-phenylbutanoic acid ethyl ester 
• 108428-37-1 N-(L-alanyl)-N-(2-indanyl)glycine tert-butyl ester oxalate 

Downstream Products

• 83435-62-5 N--L-alanyl>-N-(indan-2-yl)glycine 
• 101820-31-9 N-(2,3-dihydro-1H-inden-2-yl)-N--L-alanyl>glycine hydrochloride 
• 83398-08-7 Delaprilat 
• 83435-67-0 delapril hydrochloride 

Relevant academic research and scientific papers

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

Method for producing indan derivatives

A method for producing an indan derivative represented by the formula: STR1 by condensing an N-(α-alkoxycarbonylaralkyl)-α-amino acid with an N-(indan-2-yl)glycine alkyl or aralkyl ester in the presence of a diphenyl phosphorochloridate, and a method for

Angiotensin-converting enzyme inhibitors: N-substituted glycine derivatives

We report a series of novel dipeptides, which exhibit potent in vitro angiotensin-converting enzyme (ACE) inhibition. These dipeptides embody N-substituted glycine as the COOH terminus amino acid. The dipeptide L-lysyl-N-(2,3-dihydro-1Hinden-5-yl)glycine,